CSE:INNO

InnoCan Pharma

Market:

CSE

Market Cap:

$49.1 m

Price

0.28 CAD

Change

0.00%

52 weeks high

0.35

52 weeks low

0.05

06.08

Director Interviews

In brief

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

InnoCan Pharma is taking a true pharmaceutical approach to commercializing cannabinoids

InnoCan Pharma -

Snapshot

InnoCan is developing a revolutionary injectable CBD delivery system that facilitates targeted, controlled administration of cannabinoids into the bloodstream

Watch

InnoCan Pharma - Innocan Pharma teams up with Endless Sky to manufacturer and distribute its CBD products

Director Interviews Innocan Pharma teams up with Endless Sky to manufacturer and distribute its CBD products

on 18/8/20

Innocan Pharma received U.S. FDA approval for their over the counter CBD pain relief line

Director Interviews Innocan Pharma received U.S. FDA approval for their over the counter CBD pain relief line

on 20/7/20

Innocan Pharma launches Derma CBD line in Europe

Director Interviews Innocan Pharma launches Derma CBD line in Europe

on 8/6/20

InnoCan Pharma signs deal with ADVA Biotechnology to produce Exosomes with CBD

Director Interviews Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce Exosomes with CBD

on 25/5/20

Follow us on:

© Proactive Investors 2020.

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.